Indegene Limited (BSE: 544172, NSE: INDGN), a digital-first life sciences commercialization company, has achieved a significant milestone in its industry standing. The company has been named a Leader in Life Sciences AI and Analytics Services for Commercial PEAK Matrix® Assessment 2025 by Everest Group, a leading global research and consulting firm.

Key Highlights

• Indegene recognized for its wide-ranging AI and Analytics solutions across life sciences commercial functions
• Everest Group commends Indegene's efforts to embed Generative AI and Agentic AI capabilities in its solutions portfolio
• The assessment evaluated 30 service providers on their AI and Analytics vision, capabilities, and market impact

Indegene's Strengths

Everest Group's assessment highlighted several key strengths of Indegene:

1. Comprehensive AI and Analytics Solutions: Indegene offers a broad portfolio of AI and Analytics solutions tailored for the life sciences commercial sector.

2. Domain Expertise: The company's ability to combine AI and Analytics capabilities with deep domain knowledge was noted as a unique advantage.

3. Specialized Therapy Areas: Indegene delivers contextualized commercial solutions across various therapy areas, including specialty care, oncology, and rare diseases.

4. Innovative AI Integration: The company's continued efforts to embed Generative AI and Agentic AI capabilities across its commercial solutions portfolio were praised.

5. Global Presence: With around 5,000 employees worldwide, 9 operations hubs, and 19 offices across North America, Europe, and Asia, Indegene serves the world's top 20 biopharma companies and many emerging biotech firms.

Industry Impact

Durga Ambati, Practice Director at Everest Group, commented on the evolving landscape of life sciences commercialization: "The growing emphasis on patient- and HCP-centricity to deliver superior customer experiences has modernized commercialization strategies, placing data, analytics, and AI at the core of life sciences enterprises' go-to-market efforts."

Vivek Ghai, EVP-Enterprise Commercial Solutions at Indegene, emphasized the company's focus on responsible AI scaling: "Our focus is on helping clients scale AI responsibly - prioritizing use cases that drive measurable outcomes, integrating seamlessly with enterprise ecosystems, and delivering solutions that are not just innovative, but production-ready from day one."

This recognition by Everest Group underscores Indegene's commitment to innovation and its ability to deliver value to its clients in the rapidly evolving life sciences sector. As the industry continues to embrace AI and analytics, Indegene's leadership position positions it well to support the digital transformation of life sciences companies worldwide.

Indegene Limited (BSE: 544172, NSE: INDGN) has been named a Leader in Life Sciences AI and Analytics Services for Commercial PEAK Matrix® Assessment 2025 by Everest Group, a leading global research and consulting firm. This recognition underscores Indegene's expertise in providing AI and Analytics solutions across life sciences commercial functions.

Key Highlights

• Indegene's AI and Analytics capabilities acknowledged across life sciences commercial functions
• Recognition for embedding Generative AI and Agentic AI capabilities in solutions portfolio
• Commendation for combining AI and Analytics with domain knowledge in specialty care, oncology, and rare diseases
• Evaluation based on vision, capabilities, and market impact among 30 service providers

Everest Group's Assessment

Everest Group highlighted Indegene's unique ability to combine AI and Analytics capabilities with deep domain knowledge. This combination allows Indegene to deliver contextualized commercial solutions across various therapy areas, including specialty care, oncology, and rare diseases.

Durga Ambati, Practice Director at Everest Group, stated, "Indegene's broad portfolio of solutions within its NEXT platform, as well as its continued investments in embedding GenAI and Agentic AI across its capabilities, are well-complemented by its diverse therapeutic knowledge and strong market-facing assets."

Indegene's AI Strategy

Indegene's unified, enterprise-wide AI approach embeds production-ready solutions across commercial operations. This strategy aims to help life sciences companies achieve significant operational efficiencies and productivity gains, accelerating their journey towards being future-ready.

Vivek Ghai, EVP-Enterprise Commercial Solutions at Indegene, commented, "Our focus is on helping clients scale AI responsibly - prioritizing use cases that drive measurable outcomes, integrating seamlessly with enterprise ecosystems, and delivering solutions that are not just innovative, but production-ready from day one."

Company Profile

Indegene Limited is a digital-first, life sciences commercialization company that serves the world's top 20 biopharma companies and many emerging biotech firms. With around 5,000 employees worldwide, Indegene operates through 9 operations hubs and 19 offices across North America, Europe, and Asia.

The company combines healthcare expertise with a digital-first approach to help pharma, biotech, and medical device companies commercialize their products effectively and efficiently throughout their lifecycle.

This latest recognition by Everest Group further solidifies Indegene's position as a trusted transformation partner for life sciences organizations in the rapidly evolving landscape of AI and analytics-driven commercialization strategies.